Evidence map›Paper›PMID 40022528›Full record

ReviewJournal of diabetes science and technology2025

The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.

Sujatha Seetharaman, Eda Cengiz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sujatha SeetharamanDivision of Pediatric Endocrinology & Diabetes, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4329-3996
Eda CengizDivision of Pediatric Endocrinology & Diabetes, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7992-9506

Funding

Training Program in Pediatric EndocrinologyT32DK007161 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian J Feldman, STEPHEN E GITELMAN · 1986 to 2026
$6.2M
NIDDK NIH HHS T32 DK007161
6 · The paper itself

Abstract

Type 1 diabetes (T1D) necessitates lifelong insulin therapy due to the autoimmune destruction of insulin-producing pancreatic beta cells. Despite advancements in diabetes technology and insulin formulations, maintaining optimal glycemic outcomes remains challenging in these individuals. Obesity, accompanied by insulin resistance, is common not only in type 2 diabetes (T2D) but also in many individuals with T1D. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved for T2D and obesity, are now being explored for off-label use in individuals with T1D. This review examines their efficacy, safety, and potential benefits in T1D management. We reviewed articles published up to May 2024 from databases like PubMed and Scopus, mainly focusing on human studies of GLP-1 RAs in T1D, as well as cardiorenal and metabolic outcomes in individuals with T2D and obesity. Semaglutide and other GLP-1 RAs showed significant improvements in glycemic outcomes, hemoglobin A

Indexed as

Diabetes Mellitus, Type 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsBlood GlucoseDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHumansObesitySemaglutideTreatment OutcomeBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutideglucagon-like peptide receptor agonistsliraglutidesemaglutidetirzepatidetype 1 diabetes

Identifiers

PMID40022528
PMCPMC11686489

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.